Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330385 | 0.88 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4DPP4BCHE | |
| SCHEMBL29117075 | 0.88 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1BCHE | |
| SCHEMBL7932145 | 0.85 | CYSLTR2 (0.38) | SLC6A2SLC6A3SLC6A4DPP4CYSLTR2 | |
| SCHEMBL7932142 | 0.85 | CYSLTR2 (0.38) | SLC6A2SLC6A3SLC6A4DPP4CYSLTR2 | |
| SCHEMBL7646825 | 0.85 | CYSLTR2 (0.38) | SLC6A2SLC6A3SLC6A4DPP4CYSLTR2 | |
| SCHEMBL7936083 | 0.85 | CYSLTR2 (0.38) | SLC6A2SLC6A3SLC6A4DPP4CYSLTR2 | |
| SCHEMBL7936081 | 0.85 | CYSLTR2 (0.38) | SLC6A2SLC6A3SLC6A4DPP4CYSLTR2 | |
| SCHEMBL13627639 | 0.80 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL19895392 | 0.80 | CYSLTR2 (0.40) | CYSLTR2CYSLTR1BCHE | |
| SCHEMBL19732916 | 0.80 | CYSLTR2 (0.40) | CYSLTR2CYSLTR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101547890-A | Catalytic asymmetric synthesis of primary amines via borane reduction of oxime ethers using spiroborate esters | INTELLECTUAL PROPERTY AND TECH (US) | 2009-09-30 | — | — | CN | disclosed |
| EP-2061748-A2 | CATALYTIC ASYMMETRIC SYNTHESIS OF PRIMARY AMINES VIA BORANE REDUCTION OF OXIME ETHERS USING SPIROBORATE ESTERS | Office Of Intellectual Property And Technology (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008027740-A2 | CATALYTIC ASYMMETRIC SYNTHESIS OF PRIMARY AMINES VIA BORANE REDUCTION OF OXIME ETHERS USING SPIROBORATE ESTERS | OFFICE OF INTELLECTUAL PROPERTY AND TECHNOLOGY (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20030149306-A1 | Process for the preparation of polymorph of 4-(aryl)-1,2,3,4-tetrahydro-1-naphthale-namine derivative | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-08-07 | — | — | US | disclosed |
| WO-2001072684-B1 | PROCESS FOR THE PREPARATION OF POLYMORPH OF 4-(ARYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE DERIVATIVE | SUN PHARMACEUTICAL IND LTD (IN) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001072684-B1 | PROCESS FOR THE PREPARATION OF POLYMORPH OF 4-(ARYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE DERIVATIVE | SUN PHARMACEUTICAL IND LTD (IN) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001072684-A1 | PROCESS FOR THE PREPARATION OF POLYMORPH OF 4-(ARYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE DERIVATIVE | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072684-A1 | PROCESS FOR THE PREPARATION OF POLYMORPH OF 4-(ARYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE DERIVATIVE | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149306-A1 | Process for the preparation of polymorph of 4-(aryl)-1,2,3,4-tetrahydro-1-naphthale-namine derivative | NAMPT, NAT1, VNN1 | SLC6A2 79/4885SLC6A3 92/4885SLC6A4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.